← 產業報告目錄

Early Cancer Diagnosis and Genetic Testing Market Research Report by Product Type (instruments, consumables, and services), by Technology (Chromosomal Genetic Tests, Molecular Testing, Biochemical Testing, and Cellular Testing), by Causative Factors (Infectious agent, Non- Infectious Agent), by Application (Stomach (Gastric) Cancer, Cervical Cancer, Colorectal Cancer, Liver Cancer, Oral Cancer, Lymphoma, and Others), by End User (Hospitals & Clinics, Diagnostic Laboratories, and Others), by Region (North America, Europe, Asia Pacific, South America, Middle East & Africa) Forecast till 2035

出版商 Market Research Future產業別 Healthcare & Life Sciences出版日期 2026-05-02頁數 323報告編號 MRFRLS66581CR

授權報價

Single User Price$4,950 USD
Multi User Licence (up to 10 users)$5,950 USD
Enterprisewide Price (Global Site License)$7,250 USD
洽詢購買 申請 Sample

報告摘要

The Global Early Cancer Diagnosis and Genetic Testing Market is projected to reach USD 26,416.16 million by 2035, growing at a CAGR of 14.41% during 2025–2035. Rising awareness regarding preventive healthcare and increasing adoption of precision medicine are expected to support long-term market growth. Rising Focus on Early Cancer Detection and Preventive Healthcare The rising global focus on early cancer detection and preventive healthcare is playing a key role in enlarging the market for early cancer diagnosis and genetic testing on a worldwide scale. Increasing level of understanding, wider screening program implementation, and the development of technologies such as liquid biopsy and genetic testing are not only facilitating earlier diagnosis but also enhancing treatment results and lowering healthcare costs in the long run. Market Segment Insights By Product Type • Instruments – Enable accurate and efficient cancer diagnostics. • Consumables – Support continuous testing and laboratory workflows. • Services – Provide specialized diagnostic and genetic analysis support. By Technology • Chromosomal Genetic Tests – Detect chromosomal abnormalities linked to cancers. • Molecular Testing – Identifies gene mutations and cancer biomarkers. • Biochemical Testing – Measures biological markers for cancer detection. • Cellular Testing – Examines abnormal cellular changes and behaviors. By Causative Factors • Infectious Agent – Infection-related cancers drive diagnostic testing demand. • Non-Infectious Agent – Lifestyle factors increase cancer screening adoption. By Application • Stomach (Gastric) Cancer – Rising cases encourage early gastric cancer screening. • Cervical Cancer – HPV screening strengthens cervical cancer diagnosis rates. • Colorectal Cancer – Growing awareness boosts colorectal cancer testing demand. • Liver Cancer – Hepatitis-linked risks support liver cancer diagnostics. • Oral Cancer – Tobacco consumption increases oral cancer screening needs. • Lymphoma – Advanced testing improves lymphoma detection and monitoring. • Others – Diverse cancer types expand diagnostic application scope. By End User • Hospitals & Clinics – Primary centers for cancer diagnosis procedures. • Diagnostic Laboratories – Handle large-scale genetic and molecular testing. • Others – Research institutes contribute to diagnostic technology advancements. North America is leading the worldwide market for early cancer diagnosis and genetic testing due to its advanced oncology facilities, high level of healthcare expenditure, and fast adoption of liquid biopsy techniques, while Europe relies on government initiatives supporting the market and a well-established reimbursement system. On the other hand, the Asia-Pacific region is turning into the most rapidly growing market primarily due to its heavy investments in precision medicine and the increase in cancer awareness, while South America and the Middle East & Africa are showing slow but steady growth as a result of their improving healthcare infrastructures and oncology programs. Strategic Oncology Expansion In November 2025, Abbott disclosed its plan to acquire Exact Sciences for USD 21 billion with an aim to reinforce its standing in cancer screening and precision oncology diagnostics. This deal will substantially extend Abbott's portfolio of advanced diagnostics and at the same time, it will bring about a rapid development in cancer detection technologies at an early stage globally. Expanding Global Partnerships Strategic partnerships among diagnostic firms, healthcare providers, and technology companies are speeding up innovation in the worldwide market for early cancer diagnosis and genetic testing. With help from these collaborations, companies are expanding their geographical reach, enhancing their commercialization potential, and strengthening their access to leading cancer screening technologies in both developed and developing markets. Key Report Attributes • Market Size 2035: USD 26,416.16 Million • CAGR (2025-2035): 14.41% • Base Year: 2024 • Market Forecast Period: 2025-2035 Industry Segmentations Growth • By Product Type: Instruments – 13.66%, Consumables – 14.41%. • By Technology: Chromosomal Genetic Tests – 13.53%, Molecular Testing – 14.29%. • By Causative Factors: Infectious agent – 14.97%, Non- Infectious Agent – 13.85%. • By Application: Stomach (Gastric) Cancer – 16.64%, Cervical Cancer – 14.82%. • By End User: Hospitals & Clinics – 14.15%, Diagnostic Laboratories – 15.38%.
目錄 Table of Contents
TABLE OF CONTENTS 1 EXECUTIVE SUMMARY ......................... 26 2 MARKET INTRODUCTION ...................... 28 2.1 DEFINITION ................................. 28 2.2 SCOPE OF THE STUDY ............. 28 2.3 RESEARCH OBJECTIVE ........... 28 2.4 MARKET STRUCTURE ............. 29 3 RESEARCH METHODOLOGY ................ 30 3.1 OVERVIEW ................................... 30 3.2 DATA FLOW ................................. 32 3.2.1 DATA MINING PROCESS ........................................... 32 3.3 PURCHASED DATABASE: ........ 33 3.4 SECONDARY SOURCES: ........... 34 3.4.1 SECONDARY RESEARCH DATA FLOW: ....................... 35 3.5 PRIMARY RESEARCH: .............. 36 3.5.1 PRIMARY RESEARCH DATA FLOW: ........................... 37 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED .............................. 38 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ............ 38 3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ..... 39 3.6.1 REVENUE ANALYSIS APPROACH ............................... 39 3.7 DATA FORECASTING................ 40 3.7.1 DATA FORECASTING TYPE ........................................ 40 3.8 DATA MODELING ....................... 41 3.8.1 MICROECONOMIC FACTOR ANALYSIS: ...................... 41 3.8.2 DATA MODELING: .......... 42 3.9 TEAMS AND ANALYST CONTRIBUTION ..................... 44 4 MARKET DYNAMICS .............................. 46 4.1 INTRODUCTION .......................... 46 4.2 DRIVERS ........................................ 47 4.2.1 RISING GLOBAL CANCER INCIDENCE ......................... 47 4.2.2 GROWING EMPHASIS ON EARLY DETECTION AND PREVENTIVE HEALTHCARE....... 47 4.2.3 INCREASED AWARENESS OF HEREDITARY AND INFECTION-RELATED CANCERS ............................................... 48 4.2.4 EXPANSION OF PRECISION AND PERSONALIZED MEDICINE .................................. 49 4.3 RESTRAINTS ............................... 50 4.3.1 HIGH COST OF ADVANCED DIAGNOSTIC TESTS ......... 50 4.3.2 LIMITED REIMBURSEMENT AND INSURANCE COVERAGE ...................................... 51 4.3.3 REGULATORY AND COMPLIANCE CHALLENGES......... 51 4.4 OPPURTUNITIES ........................ 52 4.4.1 EXPANSION IN EMERGING ECONOMIES ..................... 52 4.4.2 MULTI-CANCER EARLY DETECTION (MCED) AND LIQUID BIOPS ............................. 53 4.4.3 COLLABORATIVE PARTNERSHIPS AND STRATEGIC ALLIANCES ............................ 54 4.4.4 EXPANSION IN BIOCHEMICAL AND CELLULAR TESTING ....................................... 54 5 INDUSTRY TREND ANALYSIS ............... 56 5.1 REGULATORY ENVIRONMENT & COMPLIANCE ....... 56 5.2 TECHNOLOGICAL TRENDS & INNOVATION ................ 58 5.3 PATIENT DEMOGRAPHICS & DISEASE BURDENS ..... 62 5.4 PRICING ANALYSIS & REIMBURSEMENT DYNAMICS ....................................... 66 5.4.1 PRICING ANALYSIS ........ 66 5.4.1.1 NORTH AMERICA ............................................. 66 5.4.1.1.1 NORTH AMERICA PRICING ANALYSIS, BY PRODUCT ................................ 66 5.4.1.2 EUROPE ................ 66 5.4.1.2.1 EUROPE PRICING ANALYSIS, BY PRODUCT.............................................. 66 5.4.1.3 APAC .................... 66 5.4.1.3.1 APAC PRICING ANALYSIS, BY PRODUCT ...... 66 5.4.1.4 REST OF THE WORLD ........................................ 66 5.4.1.4.1 REST OF THE WORLD PRICING ANALYSIS, BY PRODUCT .......................... 66 5.4.2 REIMBURSEMENT DYNAMICS ................................... 67 5.5 PESTLE ANALYSIS .................... 67 5.5.1 POLITICAL FACTORS ..... 67 5.5.2 ECONOMIC FACTORS ............................................... 68 5.5.3 SOCIAL FACTORS .......... 68 5.5.4 TECHNOLOGICAL FACTORS ...................................... 69 5.5.5 LEGAL FACTORS ........... 69 5.5.6 ENVIRONMENTAL FACTORS ..................................... 69 5.6 PORTER’S FIVE FORCES MODEL ..................................... 70 5.6.1 THREAT OF NEW ENTRANTS ..................................... 71 5.6.2 BARGAINING POWER OF SUPPLIERS ......................... 72 5.6.3 BARGAINING POWER OF BUYERS .............................. 72 5.6.4 THREAT OF SUBSTITUTES ........................................ 72 5.6.5 INDUSTRY RIVALRY ....... 73 5.7 PRODUCT PIPELINE ANALYSIS ....................................... 73 5.7.1 PRODUCT PIPELINE ANALYSIS .................................. 73 6 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY PRODUCT TYPE 75 6.1 OVERVIEW ................................... 75 6.2 INSTRUMENTS........................... 76 6.3 CONSUMABLES .......................... 76 6.4 SERVICES ..................................... 77 7 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET BY TECHNOLOGY 78 7.1 OVERVIEW ................................... 78 7.2 CHROMOSOMAL GENETIC TESTS .................................. 80 7.3 MOLECULAR TESTING ............ 80 7.3.1 NEXT-GENERATION SEQUENCING (NGS) ................... 81 7.3.2 POLYMERASE CHAIN REACTION (PCR) ...................... 81 7.3.3 IMMUNOHISTOCHEMISTRY (IHC) .............................. 81 7.3.4 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ........ 82 7.3.5 OTHERS ........................ 82 7.4 BIOCHEMICAL TESTING ......... 82 7.5 CELLULAR TESTING ................. 83 7.5.1 FLOW CYTOMETRY ........ 83 7.5.2 IMMUNOPHENOTYPING ............................................ 83 7.5.3 CELL IMAGING .............. 84 7.5.4 SINGLE-CELL ANALYSIS ............................................ 84 7.5.5 OTHERS ........................ 84 8 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET BY CAUSATIVE FACTOR ............. 86 8.1 OVERVIEW ................................... 86 8.2 INFECTIOUS AGENT ................. 87 8.2.1 VIRUS ........................... 88 8.2.2 EBV VIRUS .................... 88 8.2.3 HPV VIRUS .................... 89 8.2.4 HEPATITIS VIRUS (HBV) ........................................... 89 8.2.5 MERKEL CELL POLYOMAVIRUS ................................. 90 8.2.6 OTHERS ........................ 90 8.2.7 BACTERIA ..................... 90 8.2.7.1 HELICOBACTER PYLORI .................................... 90 8.2.7.2 SALMONELLA TYPHI ........................................ 91 8.2.7.3 CHLAMYDIA TRACHOMATIS ............................. 91 8.2.7.4 OTHERS ................ 91 8.2.8 FUNGI ........................... 91 8.2.8.1 ASPERGILLUS SPECIES ..................................... 92 8.2.8.2 CANDIDA ALBICANS ......................................... 92 8.2.8.3 OTHERS ................ 93 8.3 NON-INFECTIOUS AGENT ...... 93 9 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET BY APPLICATION 95 9.1 OVERVIEW ................................... 95 9.2 STOMACH (GASTRIC) CANCER ........................................ 96 9.3 CERVICAL CANCER ................... 97 9.4 COLORECTAL CANCER ............ 97 9.5 LIVER CANCER ........................... 97 9.6 ORAL CANCER ............................ 98 9.7 LYMPHOMA ................................ 98 10 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET BY END USER ..... 100 10.1 OVERVIEW ................................... 100 10.2 HOSPITALS & CLINICS ............. 101 10.3 DIAGNOSTIC LABORATORIES .......................................... 101 10.4 OTHERS ......................................... 102 11 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY REGION ... 103 11.1 OVERVIEW ................................... 103 11.2 NORTH AMERICA ...................... 105 11.2.1 US................................. 112 11.2.2 CANADA ....................... 117 11.3 EUROPE ......................................... 123 11.3.1 GERMANY ..................... 130 11.3.2 FRANCE ........................ 135 11.3.3 UK ................................ 140 11.3.4 SPAIN ........................... 145 11.3.5 ITALY ............................ 150 11.3.6 RUSSIA ......................... 154 11.3.7 REST OF EUROPE ........... 160 11.4 ASIA-PACIFIC .............................. 165 11.4.1 CHINA ........................... 173 11.4.2 INDIA ............................ 178 11.4.3 SOUTH KOREA ............... 189 11.4.4 MALAYSIA .................... 195 11.4.5 THAILAND ..................... 200 11.4.6 INDONESIA .................... 206 11.4.7 REST OF ASIA-PACIFIC ............................................. 211 11.5 SOUTH AMERICA ...................... 217 11.5.1 BRAZIL .......................... 225 11.5.2 MEXICO ........................ 230 11.5.3 ARGENTINA .................. 235 11.5.4 REST OF SOUTH AMERICA ........................................ 241 11.6 MIDDLE EAST AND AFRICA .............................................. 247 11.6.1 GCC COUNTRIES............ 255 11.6.2 SOUTH AFRICA .............. 260 11.6.3 REST OF MEA ................ 266 12 COMPETITIVE LANDSCAPE .................. 273 12.1 INTRODUCTION .......................... 273 12.2 MARKET SHARE ANALYSIS, 2024 ................................. 274 12.3 COMPETITOR DASHBOARD............................................... 275 12.4 PUBLIC PLAYERS STOCK SUMMARY ........................... 276 12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ................................... 276 12.1 KEY DEVELOPMENTS & GROWTH STRATEGIES ...... 277 12.1.1 PRODUCT INNOVATION ............................................ 277 12.1.2 ACQUISITION ................ 277 12.1.3 COLLABORATION/PARTNERSHIP .............................. 278 13 COMPANY PROFILES ............................ 279 13.1 ABBOTT ......................................... 279 13.1.1 COMPANY OVERVIEW ............................................... 279 13.1.2 FINANCIAL OVERVIEW .............................................. 280 13.1.3 PRODUCTS/SERVICES OFFERED ................................ 280 13.1.4 KEY DEVELOPMENTS ..... 281 13.1.5 SWOT ANALYSIS ........... 282 13.1.6 KEY STRATEGIES ........... 282 13.2 F. HOFFMANN-LA ROCHE LTD ........................................ 284 13.2.1 COMPANY OVERVIEW ............................................... 284 13.2.2 FINANCIAL OVERVIEW .............................................. 285 13.2.3 PRODUCTS/SERVICES OFFERED ................................ 285 13.2.5 SWOT ANALYSIS ........... 288 13.2.6 KEY STRATEGIES ........... 288 13.3 GE HEALTHCARE ...................... 289 13.3.1 COMPANY OVERVIE ....... 289 13.3.2 FINANCIAL OVERVIEW .............................................. 290 13.3.3 PRODUCTS OFFERED ..... 290 13.3.5 SWOT ANALYSIS ........... 291 13.3.6 KEY STRATEGIES ........... 292 13.4.5 SWOT ANALYSIS ........... 296 13.5 BD ......... 298 13.5.1 COMPANY OVERVIEW ............................................... 298 13.5.2 FINANCIAL OVERVIEW .............................................. 299 13.5.3 PRODUCTS OFFERED ..... 299 13.5.5 SWOT ANALYSIS ........... 300 13.5.6 KEY STRATEGY .............. 300 13.6 SIEMENS HEALTHINEERS AG ......................................... 302 13.6.1 COMPANY OVERVIEW ............................................... 302 13.6.2 FINANCIAL OVERVIEW .............................................. 303 13.6.3 PRODUCTS/SERVICES OFFERED ................................ 303 13.6.5 SWOT ANALYSIS ........... 304 13.6.6 KEY STRATEGIES ........... 304 13.7 HOLOGIC, INC. .............................. 306 13.7.1 COMPANY OVERVIEW ............................................... 306 13.7.2 FINANCIAL OVERVIEW .............................................. 307 13.7.3 PRODUCTS OFFERED ..... 307 13.7.5 SWOT ANALYSIS ........... 308 13.7.6 KEY STRATEGIES ........... 308 13.8.5 SWOT ANALYSIS ........... 312 13.9 ILLUMINA, INC. .......................... 314 13.9.1 COMPANY OVERVIEW ............................................... 314 13.9.2 FINANCIAL OVERVIEW .............................................. 315 13.9.3 PRODUCTS OFFERED ..... 315 13.9.5 SWOT ANALYSIS ........... 316 13.9.6 KEY STRATEGY .............. 316 13.10 QUEST DIAGNOSTICS ............... 318 13.10.1 COMPANY OVERVIEW ............................................... 318 13.10.2 FINANCIAL OVERVIEW .............................................. 319 13.10.3 PRODUCTS/SERVICES OFFERED ................................ 319 13.10.4 KEY DEVELOPMENTS ..... 320 13.10.5 SWOT ANALYSIS ........... 321 13.10.6 KEY STRATEGIES ........... 321 14 DATA CITATIONS ................................... 322
圖表清單 List of Tables & Figures
LIST OF TABLES TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 43 TABLE 2 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 76 TABLE 3 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 79 TABLE 4 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 80 TABLE 5 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 83 TABLE 6 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 87 TABLE 7 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, FOR INFECTIOUS AGENT, BY TYPE, 2019–2035 (USD MILLION) 87 TABLE 8 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION) 88 TABLE 9 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION) 90 TABLE 10 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION) 92 TABLE 11 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 96 TABLE 12 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY END USER, 2019–2035 (USD MILLION) 101 TABLE 1 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY REGION, 2019-2035 103 TABLE 2 NORTH AMERICA EARLY CANCER DIAGNOSIS TESTING MARKET, BY COUNTRY, 2019-2035 106 TABLE 3 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 107 TABLE 4 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 107 TABLE 5 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 108 TABLE 6 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 108 TABLE 7 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 109 TABLE 8 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 109 TABLE 9 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 110 TABLE 10 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 110 TABLE 11 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) 111 TABLE 12 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 111 TABLE 13 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) 112 TABLE 14 US: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 112 TABLE 15 US: EARLY CANCER DIAGNOSIS TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 113 TABLE 16 US: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 113 TABLE 17 US: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 114 TABLE 18 US: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 114 TABLE 19 US: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 114 TABLE 20 US: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 115 TABLE 21 US: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 115 TABLE 22 US: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) 116 TABLE 23 US: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 116 TABLE 24 US: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) 117 TABLE 25 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 117 TABLE 26 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 118 TABLE 27 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 118 TABLE 28 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 119 TABLE 29 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 119 TABLE 30 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 120 TABLE 31 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 120 TABLE 32 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 121 TABLE 33 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) 121 TABLE 34 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 122 TABLE 35 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) 122 TABLE 36 EUROPE EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 124 TABLE 37 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 125 TABLE 38 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 125 TABLE 39 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 126 TABLE 40 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 126 TABLE 41 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 127 TABLE 42 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 127 TABLE 43 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 128 TABLE 44 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 128 TABLE 45 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) 129 TABLE 46 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 129 TABLE 47 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) 130 TABLE 48 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 130 TABLE 49 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 131 TABLE 50 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 131 TABLE 51 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 132 TABLE 52 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 132 TABLE 53 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 133 TABLE 54 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 133 TABLE 55 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) 134 TABLE 56 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 134 TABLE 57 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) 135 TABLE 58 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 135 TABLE 59 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 136 TABLE 60 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 136 TABLE 61 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 137 TABLE 62 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 137 TABLE 63 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 137 TABLE 64 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 138 TABLE 65 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 138 TABLE 66 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) 139 TABLE 67 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 139 TABLE 68 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) 140 TABLE 69 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 140 TABLE 70 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 141 TABLE 71 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 141 TABLE 72 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 142 TABLE 73 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 142 TABLE 74 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 142 TABLE 75 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 143 TABLE 76 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) 143 TABLE 77 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 144 TABLE 78 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) 144 TABLE 79 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 145 TABLE 80 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 145 TABLE 81 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 146 TABLE 82 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 146 TABLE 83 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 147 TABLE 84 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 147 TABLE 85 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 147 TABLE 86 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 148 TABLE 87 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) 148 TABLE 88 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 149 TABLE 89 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) 149 TABLE 90 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 150 TABLE 91 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 150 TABLE 92 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 151 TABLE 93 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 151 TABLE 94 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 152 TABLE 95 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 152 TABLE 96 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 152 TABLE 97 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 153 TABLE 98 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) 153 TABLE 99 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 153 TABLE 100 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) 154 TABLE 101 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 154 TABLE 102 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 155 TABLE 103 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 155 TABLE 104 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 156 TABLE 105 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 156 TABLE 106 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 157 TABLE 107 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 157 TABLE 108 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 158 TABLE 109 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) TABLE 110 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) TABLE 111 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) TABLE 112 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) TABLE 113 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) TABLE 114 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 161 TABLE 115 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 161 TABLE 116 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 162 TABLE 117 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 162 TABLE 118 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) TABLE 119 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) TABLE 120 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) TABLE 121 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) TABLE 122 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) TABLE 123 ASIA-PACIFIC EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY COUNTRY, 2019-2035 (USD MILLION) TABLE 124 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION) TABLE 125 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION) TABLE 126 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 168 TABLE 127 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 169 TABLE 128 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 169 TABLE 129 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD MILLION) TABLE 130 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION) TABLE 131 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION) TABLE 132 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION) TABLE 133 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION) TABLE 134 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION) TABLE 135 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION) TABLE 136 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION) TABLE 137 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 174 TABLE 138 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) TABLE 139 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) TABLE 140 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD MILLION) TABLE 141 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION) TABLE 142 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION) TABLE 143 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION) TABLE 144 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION) TABLE 145 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION) TABLE 146 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION) TABLE 147 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION) TABLE 148 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 179 TABLE 149 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 180 TABLE 150 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 180 TABLE 151 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 181 TABLE 152 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION) TABLE 153 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION) TABLE 154 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION) TABLE 155 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION) TABLE 156 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION) TABLE 157 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION) TABLE 158 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION) TABLE 159 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 185 TABLE 160 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 185 TABLE 161 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) TABLE 162 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD MILLION) TABLE 163 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION) TABLE 164 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION) TABLE 165 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION) TABLE 166 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION) TABLE 167 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION) TABLE 168 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION) TABLE 169 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION) TABLE 170 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 190 TABLE 171 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 191 TABLE 172 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 191 TABLE 173 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 192 TABLE 174 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION) TABLE 175 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION) TABLE 176 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION) TABLE 177 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION) TABLE 178 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION) TABLE 179 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION) TABLE 180 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION) TABLE 181 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 196 TABLE 182 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 196 TABLE 183 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 197 TABLE 184 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 197 TABLE 185 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION) TABLE 186 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION) TABLE 187 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION) TABLE 188 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION) TABLE 189 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION) TABLE 190 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION) TABLE 191 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION) 199 TABLE 192 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 201 TABLE 193 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 202 TABLE 194 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 202 TABLE 195 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 203 TABLE 196 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION) TABLE 197 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION) TABLE 198 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION) TABLE 199 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION) TABLE 200 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION) TABLE 201 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION) TABLE 202 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION) TABLE 203 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 207 TABLE 204 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 207 TABLE 205 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 208 TABLE 206 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 208 TABLE 207 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION) TABLE 208 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION) TABLE 209 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION) TABLE 210 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION) TABLE 211 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION) TABLE 212 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION) TABLE 213 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION) TABLE 214 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 212 TABLE 215 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 213 TABLE 216 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 213 TABLE 217 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019 2035 (USD MILLION) 214 TABLE 218 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION) 214 TABLE 219 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION) 215 TABLE 220 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION) 215 TABLE 221 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION) 216 TABLE 222 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION) TABLE 223 SOUTH AMERICA EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY COUNTRY, 2019-2035 (USD MILLION) TABLE 224 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION) TABLE 225 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION) TABLE 226 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 220 220 TABLE 227 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 221 TABLE 228 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 221 TABLE 229 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 222 TABLE 230 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION) TABLE 231 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION) TABLE 232 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION) TABLE 233 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION) TABLE 234 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION) TABLE 235 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION) TABLE 236 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION) 225 TABLE 237 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 226 TABLE 238 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 226 TABLE 239 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) TABLE 240 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD MILLION) TABLE 241 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION) TABLE 242 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION) TABLE 243 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION) TABLE 244 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION) TABLE 245 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION) TABLE 246 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION) TABLE 247 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION) TABLE 248 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 231 TABLE 249 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 231 TABLE 250 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 232 TABLE 251 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD MILLION) TABLE 252 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION) TABLE 253 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION) TABLE 254 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION) TABLE 255 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION) TABLE 256 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION) TABLE 257 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION) TABLE 258 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION) TABLE 259 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 236 TABLE 260 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 237 TABLE 261 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 237 TABLE 262 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD MILLION) TABLE 263 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION) TABLE 264 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION) TABLE 265 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION) TABLE 266 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION) TABLE 267 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION) TABLE 268 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 241 TABLE 269 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION) 241 TABLE 270 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 242 TABLE 271 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 242 TABLE 272 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 243 TABLE 273 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 243 TABLE 274 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION) 244 TABLE 275 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION) 244 TABLE 276 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION) 245 TABLE 277 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION) 245 TABLE 278 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION) 246 TABLE 279 MIDDLE EAST AND AFRICA EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 248 TABLE 280 MIDDLE EAST AND AFRICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 249 TABL LIST OF FIGURES FIGURE 1 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET: STRUCTURE 29 FIGURE 1 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET: GROWTH FACTOR ANALYSIS (2019-2035) 46 FIGURE 2 DRIVER IMPACT ANALYSIS: GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET 50 FIGURE 3 RESTRAINT IMPACT ANALYSIS: GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET 52 FIGURE 4 PORTER FIVE FORCE ANALYSIS: GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET 71 FIGURE 5 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, PRODUCT TYPE SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 75 FIGURE 6 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY PRODUCT TYPE, 2024 & 2035 (USD MILLION) 75 FIGURE 7 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), BY PRODUCT TYPE, 2024 77 FIGURE 8 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, TECHNOLOGY SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 78 FIGURE 9 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY TECHNOLOGY, 2024 & 2035 (USD MILLION) 79 FIGURE 10 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), BY TECHNOLOGY, 2024 85 FIGURE 11 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, CAUSATIVE FACTOR SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 86 FIGURE 12 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY CAUSATIVE FACTOR, 2024 & 2035 (USD MILLION) 86 FIGURE 13 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), CAUSATIVE FACTOR, 2024 93 FIGURE 14 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, APPLICATION SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 95 FIGURE 15 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY APPLICATION, 2024 & 2035 (USD MILLION) 96 FIGURE 16 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), APPLICATION, 2024 99 FIGURE 17 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, END USER SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 100 FIGURE 18 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY END USER, 2024 & 2035 (USD MILLION) 100 FIGURE 19 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), END USER, 2024 102 FIGURE 20 GLOBAL MARKET ANALYSIS: EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, 2019-2035 (USD MILLION) 103 FIGURE 1 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY REGION, 2024 (% SHARE) 104 FIGURE 2 NORTH AMERICA MARKET ANALYSIS: EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, 2019-2035 (USD MILLION) 105 FIGURE 3 NORTH AMERICA EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION) 106 FIGURE 4 NORTH AMERICA EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), BY COUNTRY, 2024 106 FIGURE 5 EUROPE MARKET ANALYSIS: EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, 2019-2035 (USD MILLION) 123 FIGURE 6 EUROPE EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION) 124 FIGURE 7 EUROPE EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), BY COUNTRY, 2024 125 FIGURE 8 ASIA-PACIFIC MARKET SWOT ANALYSIS: EARLY CANCER DIAGNOSIS AND GENETIC TESTING 165 FIGURE 9 ASIA-PACIFIC EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION) 165 FIGURE 10 ASIA-PACIFIC EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), BY COUNTRY, 2024 167 FIGURE 11 SOUTH AMERICA MARKET SWOT ANALYSIS: EARLY CANCER DIAGNOSIS AND GENETIC TESTING 217 FIGURE 12 SOUTH AMERICA EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION) 218 FIGURE 13 SOUTH AMERICA EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), BY COUNTRY, 2024 219 FIGURE 14 MIDDLE EAST AND AFRICA MARKET SWOT ANALYSIS: EARLY CANCER DIAGNOSIS AND GENETIC TESTING 247 FIGURE 15 MIDDLE EAST AND AFRICA EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION) 248 FIGURE 16 MIDDLE EAST AND AFRICA EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), BY COUNTRY, 2024 249 FIGURE 17 EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024 FIGURE 18 COMPETITOR DASHBOARD: EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET FIGURE 19 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT FIGURE 20 ABBOTT: SWOT ANALYSIS FIGURE 21 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT FIGURE 22 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS FIGURE 23 GE HEALTHCARE: SWOT ANALYSIS FIGURE 25 QIAGEN: SWOT ANALYSIS FIGURE 26 BD: SWOT ANALYSIS FIGURE 27 SIEMENS HEALTHINEERS AG: FINANCIAL OVERVIEW SNAPSHOT FIGURE 28 SIEMENS HEALTHINEERS AG: SWOT ANALYSIS FIGURE 29 HOLOGIC, INC.: SWOT ANALYSIS FIGURE 31 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS FIGURE 32 ILLUMINA, INC.: SWOT ANALYSIS FIGURE 33 QUEST DIAGNOSTICS: FINANCIAL OVERVIEW SNAPSHOT FIGURE 34 QUEST DIAGNOSTICS: SWOT ANALYSIS

提及公司

AbbottF. Hoffmann-La Roche LtdGE HealthcareQIAGENBDSiemens Healthineers ADHologicInc.Thermo Fisher Scientific Inc.IlluminaInc.Quest Diagnostics

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們